Nicardipine: Nursing Drug Guide, IV Titration & Hypotension
IV nicardipine lowers blood pressure within minutes when rates climb too fast—symptomatic hypotension, reflex tachycardia, and cerebral hypoperfusion can follow. Line discipline matters: wrong concentration, shared tubing, small veins, and missed 12-hour site rotation drive extravasation and phlebitis.
Nicardipine (Cardene I.V.) is a titratable IV calcium channel blocker for short-term hypertension control. Blood pressure begins to fall within minutes of a rate increase; about half the ultimate drop occurs within 45 minutes. If hypotension or excessive tachycardia develops, discontinue the infusion and restart only at low rates after stabilization. Advanced aortic stenosis is contraindicated. Administer through large peripheral or central veins, rotate peripheral sites every 12 hours, and never co-infuse other drugs in the same line.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Nicardipine safety is titration plus line discipline: verify concentration (0.1 or 0.2 mg/mL), program mg/hour against mL/hour, monitor blood pressure and heart rate after every change, rotate peripheral sites every 12 hours, and coordinate oral antihypertensive transition before stopping the infusion.
Most common brand names
IV nicardipine is marketed as Cardene I.V. (premixed infusion bags and vials for pharmacy preparation). Oral nicardipine is available as Cardene (immediate-release capsules) and Cardene SR (sustained-release capsules) for maintenance therapy after IV bridging.
Verify the MAR lists generic nicardipine plus the specific brand and concentration—pump programming errors often trace to confusing 0.1 mg/mL premixed bags with 0.2 mg/mL bags or undiluted 25 mg/10 mL vials.
Why we give it — Indications
Per Cardene I.V. prescribing information, nicardipine is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable—common in perioperative, neurocritical, obstetric, and ICU settings where rapid, titratable blood pressure control is required.
| Use | Detail |
|---|---|
| Acute hypertension (IV) | Continuous infusion when oral antihypertensives cannot be used; titrate to prescriber-defined targets while monitoring for hypertension symptoms |
| Bridge to oral therapy | Short-term IV control while Cardene or Cardene SR is initiated—plan transition before discontinuation to limit rebound |
| Hypertensive urgency with end-organ risk | Rapid lowering when ordered to reduce risk of stroke or other complications per prescriber plan—not a substitute for definitive diagnosis |
| Oral maintenance (after IV) | Cardene capsules or Cardene SR when patient can take oral therapy and IV nicardipine is no longer required |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Nicardipine is a dihydropyridine calcium channel blocker that inhibits calcium influx in vascular smooth muscle, producing arteriolar dilation and reduced systemic vascular resistance. Blood pressure falls within minutes of IV infusion rate changes because the drug acts directly on peripheral resistance rather than requiring days of oral accumulation.
Like other vasodilators used for acute hypertension—including non-dihydropyridine agents such as diltiazem—nicardipine can provoke reflex tachycardia when blood pressure drops abruptly, increasing myocardial oxygen demand in patients with coronary disease.
Onset, peak, duration, and half-life
| Parameter | Value (labeling) | Nursing relevance |
|---|---|---|
| Onset | Blood pressure begins to fall within minutes of infusion | Reassess blood pressure after every rate increase—do not wait a full hour for effect |
| Magnitude over time | About 50% of the ultimate decrease occurs within ~45 minutes | Expect continued drift after an early “good” reading; avoid stacking upward titrations too quickly |
| Gamma half-life | 14.4 hours (terminal phase) | Offset is faster than terminal half-life suggests during active infusion because concentrations decline when the pump stops |
| Post-infusion decline | ~50% decrease in plasma concentrations during the first 2 hours after stopping | Hypotension may improve after stop, but blood pressure can rebound if oral therapy is not in place |
| Offset after discontinuation | ~50% of pharmacodynamic effect reverses within ~30 minutes | Transition to oral antihypertensives before stopping IV—do not discontinue without a coverage plan |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
Individualize IV titration to prescriber blood pressure targets. Program the pump in mg/hour and verify the equivalent mL/hour for the bag or diluted vial concentration before every rate change.
IV continuous infusion (Cardene I.V. labeling)
Concentrations and pump math
| Product | Concentration | Preparation | Example: 5 mg/hour = |
|---|---|---|---|
| Premixed bag | 0.1 mg/mL or 0.2 mg/mL | No dilution required | 50 mL/hr at 0.1 mg/mL; 25 mL/hr at 0.2 mg/mL |
| Vial | 25 mg/10 mL (2.5 mg/mL) | Dilute to 0.1 mg/mL before infusion | 50 mL/hr after proper dilution to 0.1 mg/mL |
On a small screen, swipe or scroll sideways to see the full table.
Discontinuation and oral transition
- About half of the blood pressure effect reverses within ~30 minutes after stopping the infusion—plan oral coverage before discontinuation
- When transitioning to oral nicardipine (Cardene or Cardene SR), give the first oral dose 1 hour before stopping the IV infusion per labeling
- When switching to a different oral antihypertensive class, coordinate timing with pharmacy and prescriber so IV is not stopped without active oral orders
Hepatic / renal impairment: Labeling advises titrating slowly and monitoring blood pressure closely—no fixed dose reduction table; expect heightened hypotension risk during upward titration.
Missed dose: Not applicable to continuous infusion—if the infusion was interrupted, verify line patency, solution stability, and prescriber direction before restarting at a conservative rate.
Before you give it — Safety check
Each 2.5 mg/hour increase can drop blood pressure within minutes. Symptomatic hypotension with reflex tachycardia worsens myocardial oxygen balance in patients with angina or heart failure—decrease the rate first, then notify the prescriber.
Pretreatment checks
- Perform medication reconciliation—document oral antihypertensives held or continued and confirm transition orders before planned IV stop
- Screen for advanced aortic valve stenosis—the only labeled contraindication
- Establish blood pressure targets, maximum infusion rate, and reassessment interval (every 5–15 minutes during upward titration)
- Confirm bag concentration (0.1 vs 0.2 mg/mL) or vial dilution to 0.1 mg/mL; independent double-check pump mg/hour and mL/hour
- Assess baseline heart rate, perfusion, urine output, and neurologic status; review history of coronary disease and heart failure
Contraindications
- Advanced aortic stenosis
Warnings (labeling)
- Hypotension and reflex tachycardia: Decrease infusion rate when blood pressure falls below goal or heart rate rises excessively
- Angina exacerbation: Reflex tachycardia and lowered diastolic pressure can worsen myocardial ischemia—report chest symptoms immediately
- Heart failure: Titrate slowly, especially when beta-blockers are also used—monitor for pulmonary edema and poor perfusion
- Hepatic / renal impairment: Titrate slowly; blood pressure response may be exaggerated
- Local irritation / extravasation: Use a large peripheral or central vein; rotate infusion site at least every 12 hours; avoid hand, wrist, and other small veins; never give intra-arterially
Important interactions
| Drug / scenario | Effect | Nursing action |
|---|---|---|
| Beta-blockers (especially in heart failure) | Additive blood pressure lowering; HF patients need slow titration per label | Coordinate rate changes with prescriber; do not stack upward titrations while patient is hypotensive |
| Cimetidine | Increased nicardipine exposure possible | Review MAR for H2-blocker or PPI substitution; monitor for exaggerated hypotension |
| Cyclosporine / tacrolimus | Nicardipine may raise immunosuppressant levels | Flag for pharmacy review; monitor for toxicity per transplant protocol |
| Other vasodilators | Additive hypotension with nitroglycerin or concurrent IV antihypertensives such as labetalol | Clarify which agent is primary; reassess blood pressure after any second-agent bolus or rate change |
| Incompatible solutions in same line | Sodium bicarbonate and lactated Ringer’s (vial labeling) must not combine with nicardipine in the same tubing | Dedicated line or verify Y-site compatibility with pharmacy before co-infusion |
On a small screen, swipe or scroll sideways to see the full table.
Preparation, compatibility, and stability
| Formulation | Preparation | Compatibility notes |
|---|---|---|
| Premixed infusion (0.1 or 0.2 mg/mL) | Ready to administer—do not dilute | Verify bag label concentration before programming pump; protect from light per institutional policy |
| Vial 25 mg/10 mL | Dilute to final concentration of 0.1 mg/mL per labeling before infusion | Pharmacy preparation preferred; nurse verifies dilution label matches pump programming |
| Incompatible in same line | Do not combine with sodium bicarbonate or lactated Ringer’s in the same tubing (vial label) | Use dedicated nicardipine line or confirm compatible primary fluid with pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Stability after preparation and beyond-use dating follow manufacturer and pharmacy guidance for the specific product used—obtain a new bag or diluted solution when expiry time is reached rather than extending beyond labeling.
Administration
Route: Intravenous continuous infusion only for Cardene I.V. Oral Cardene and Cardene SR are separate formulations—do not crush SR capsules unless pharmacy directs.
- Administer through a large vein with adequate blood flow; rotate the infusion site at least every 12 hours
- Avoid hand, wrist, and other small veins; monitor the site for erythema, swelling, or pain suggesting extravasation
- Never administer intra-arterially—arteriolar dilation can cause limb ischemia
- Program and verify infusion using IV infusion pump setup standards—mg/hour order, concentration on bag, mL/hour display, and line label
- Independent double-check for every upward titration during the 5–15 minute reassessment window
- Do not administer other medications through the nicardipine line unless pharmacy confirms compatibility
Local irritation and extravasation risk rise in small veins. Label the catheter and pump channel “Nicardipine only” and communicate site-rotation schedule at handoff.
Expected therapeutic response
- Measurable blood pressure decline within minutes after a rate increase when titrated per protocol
- Approximately half of the expected total reduction often occurs within ~45 minutes—continue cautious monitoring before additional upward titration
- Blood pressure stabilizes in the ordered range without symptomatic hypotension on serial blood pressure measurement
- After goal is reached with rapid titration, rate decreases toward ~3 mg/hour maintenance per labeling
- Oral antihypertensive orders are active—or first oral nicardipine dose given 1 hour before stop when continuing the same drug orally
Red flags — Stop and act
Escalate immediately for perfusion failure, neurologic change, extravasation, or uncontrolled overshoot during titration.
- Systolic or mean arterial pressure below prescriber threshold with dizziness, confusion, or cool clammy skin—decrease rate and notify prescriber
- New or worsening chest pain or ischemic changes on monitor during reflex tachycardia or hypotension
- Sustained rapid heart rate with hypotension or angina symptoms—decrease infusion rate per label
- Oliguria, rising lactate, or neurologic change suggesting hypoperfusion during aggressive titration
- Infusion site pain, swelling, blanching, or cool extremity—stop infusion, disconnect, and initiate extravasation protocol
- Blood pressure rebound above baseline within 30–60 minutes after stop when no oral coverage was started
Adverse effects
| Adverse effect | Frequency (labeling) | Nursing response |
|---|---|---|
| Headache | 15% | Assess blood pressure—may reflect rapid lowering; avoid treating as isolated pain without vitals |
| Hypotension | 6% | Decrease infusion rate per label; support perfusion per protocol; document for titration decisions |
| Tachycardia | 4% | Evaluate as reflex response to BP drop; decrease rate if hypotension present; monitor for ischemia |
| Nausea / vomiting | 5% | Rule out hypotension and perfusion change; document timing with rate changes |
| Local infusion-site irritation | Label warning | Rotate site q12h; move to larger vein; monitor for extravasation |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose presents as excessive hypotension and reflex tachycardia. There is no specific antidote listed in Cardene I.V. prescribing information.
Management (labeling)
- Discontinue or decrease the nicardipine infusion immediately
- Support blood pressure with IV fluids, vasopressors, and positioning per protocol and prescriber orders
- Monitor heart rate, perfusion, and neurologic status until stable
Antidote: None—treatment is supportive.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Cardene I.V. vs clevidipine (Cleviprex)—both are IV dihydropyridine vasodilators with different concentrations, titration steps, and line rules; verify drug name on bag and MAR
- Nicardipine vs nifedipine—similar names; confirm generic name and route before pump programming
- 0.1 mg/mL vs 0.2 mg/mL premixed bags—mL/hour doubles for the same mg/hour if concentration is wrong
- Undiluted 25 mg/10 mL vial vs 0.1 mg/mL bag—never infuse vial concentrate without pharmacy dilution
- mg/hour vs mL/hour—independent double-check every titration; document concentration on the pump screen
- Cardene SR vs Cardene capsules—do not substitute sustained-release for immediate-release without new orders
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Titration log | Document rate, blood pressure, and heart rate after every 2.5 mg/hour increase—minimum 5–15 minute reassessment interval |
| Overshoot recovery | Decrease rate first; avoid upward titration while patient is symptomatically hypotensive |
| Maintenance after goal | Step down toward 3 mg/hour once target reached after rapid titration—do not leave at 15 mg/hour without orders |
| Oral transition timing | First oral nicardipine dose 1 hour before IV stop when continuing same drug; otherwise confirm alternate oral agent is administered |
| Handoff | State concentration, mg/hour, mL/hour, last vitals, site location and rotation time, and oral transition status |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Advanced aortic stenosis | Contraindicated—fixed obstruction limits compensatory perfusion during vasodilation |
| Coronary artery disease / angina | Reflex tachycardia and lower diastolic pressure may worsen ischemia—slow titration and low starting rates |
| Heart failure with beta-blocker | Label warns to titrate slowly—monitor lungs, weight, and perfusion; avoid aggressive upward titration |
| Hepatic impairment | Titrate slowly; exaggerated hypotension possible—more frequent blood pressure checks |
| Renal impairment | Titrate slowly; trend creatinine on basic metabolic panel when prolonged therapy or other nephrotoxins run |
| Transplant recipients on cyclosporine or tacrolimus | Drug level interaction—pharmacy coordination and toxicity surveillance |
| Pregnancy | Pregnancy Category C per labeling—use only when benefit clearly outweighs risk per maternal-fetal team |
| Lactation | Minimally excreted in breast milk per labeling—consult prescriber and lactation resources |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure every 5–15 minutes during active upward titration; at least every 5 minutes when rates change per institutional protocol
- Heart rate and rhythm on ECG or telemetry for reflex tachycardia and ischemia
- Neurologic status, urine output, and perfusion when hypotension occurs
- Infusion site at least every 1–2 hours; rotate site every 12 hours
- Blood pressure for at least 30–60 minutes after discontinuation when oral transition was delayed
Document
- Start time, indication, concentration, initial rate, and prescriber blood pressure targets
- Each titration with paired blood pressure, heart rate, and nurse initials on double-check
- Bag or vial lot, dilution verification, and line label “Nicardipine”
- Oral transition orders—including 1-hour-before-stop oral nicardipine when applicable
Patient teaching
- This IV medicine lowers blood pressure quickly—the team will check your blood pressure often and change the pump rate based on the results
- Report dizziness, headache, chest pain, shortness of breath, nausea, or a pounding heartbeat immediately
- Keep the arm with the IV still and tell your nurse if the site burns, swells, or feels cool compared with the other arm
- When switching to pills, take the new blood pressure medicine on schedule—especially the first oral dose timed before the drip stops when your prescriber orders oral nicardipine
- Ask for help before getting out of bed; standing soon after a blood pressure drop can cause falls
The Hold Rule
Do not start or continue and contact the prescriber/pharmacist when:
- Advanced aortic stenosis documented or suspected
- Symptomatic hypotension or blood pressure below prescriber goal—decrease or hold rate and notify before re-titrating upward
- Excessive reflex tachycardia with chest pain, ischemic ECG changes, or poor perfusion
- Signs of extravasation or infusion into a hand, wrist, or intra-arterial line
- Wrong concentration programmed (undiluted vial, 0.2 mg/mL bag programmed as 0.1 mg/mL, or incompatible fluid in same line)
- No oral or alternative antihypertensive plan when discontinuation is imminent—prevent rebound within ~30 minutes
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Nicardipine is a titratable IV calcium channel blocker—nursing safety centers on concentration verification, timed reassessment after every rate increase, perfusion surveillance, and deliberate oral transition before stop.
1. Check-before-you-give protocol
- Right patient, drug, concentration (0.1 or 0.2 mg/mL premixed, or 0.1 mg/mL after vial dilution), rate in mg/hour, and line assignment
- Blood pressure target, maximum 15 mg/hour, and 5–15 minute reassessment interval written and verified
- Large-vein access confirmed; site rotation schedule documented
- Oral transition orders active or first oral nicardipine scheduled 1 hour before planned stop
2. High-alert and safety badge
Not a standalone high-alert drug on all lists — treat continuous IV titration with high-alert safeguardsISMP emphasizes independent double-checks, pump programming verification, and structured blood pressure monitoring for IV vasoactive titrations even when nicardipine is not on a facility’s standalone high-alert list.
3. Clinical workflow: hold and question rules
- If blood pressure drops below goal within minutes of a +2.5 mg/hour increase, decrease the rate first—question any new order to increase without a reassessment interval
- If oral antihypertensives are held without transition plan, clarify before discontinuing infusion
- If sodium bicarbonate or lactated Ringer’s is ordered through the same line, stop and verify compatibility with pharmacy
4. Critical teach-back questions
- “What symptoms should you report while this blood pressure drip is running?” (Dizziness, chest pain, pounding heartbeat, nausea, IV site pain.)
- “What happens to your blood pressure pills when the IV drip stops?” (Patient should name oral medicines and importance of taking the first dose on time when oral nicardipine is ordered.)
5. Care coordination
Pharmacist: Vial dilution, bag concentration verification, incompatible fluids, cyclosporine/tacrolimus level review, and transition drug selection
Prescriber / ICU / anesthesia team: Blood pressure targets, maximum infusion rate, oral agent orders (including 1-hour-before-stop nicardipine), and rebound monitoring after discontinuation
🧠 Quick mental checklist
- Advanced aortic stenosis ruled out—and bag concentration matches pump (0.1 vs 0.2 mg/mL, or diluted vial)?
- Last +2.5 mg/hour titration paired with blood pressure and heart rate—any overshoot needing rate decrease?
- Large vein with site rotation q12h—no hand, wrist, or intra-arterial administration?
- Oral transition in place—or first oral nicardipine due 1 hour before I stop this infusion?
- No bicarbonate or lactated Ringer’s in the same line as nicardipine?
Nicardipine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for nicardipine IV titration using a tabbed case (MAR, labs, vitals, and nursing notes), plus priority action, select-all-that-apply cues, trend interpretation, matrix urgency, clinical judgment, and documentation cloze items tied to hypotension, concentration errors, and oral transition timing.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Nicardipine (Cardene I.V.) 0.1 mg/mL IV infusion — current rate 10 mg/hour via dedicated peripheral line in forearm (started 90 minutes ago at 5 mg/hour)
- Metoprolol 25 mg PO daily (held this morning per anesthesia)
- Orders: maintain SBP 140–160 mmHg post–subarachnoid hemorrhage; notify if SBP <110 or HR >120
- Basic metabolic panel: sodium 138, potassium 4.1, creatinine 1.0 mg/dL (baseline 0.9)
- Hemoglobin 11.2 g/dL stable
- Cardene I.V. bag label verified 0.1 mg/mL (20 mg in 200 mL)
- 1045: BP 98/56 mmHg, HR 122 bpm, MAP 70, SpO2 97% on room air
- 1030: BP 118/68 mmHg, HR 96 bpm after rate increased from 7.5 to 10 mg/hour
- 1015: BP 162/86 mmHg, HR 88 bpm before last titration
- Urine output 28 mL/hr past 2 hours (down from 55 mL/hr)
- Patient reports dizziness and “heart racing” since last rate change
- IV site in forearm without erythema; site due for rotation at 1200 (12-hour schedule)
- Oral nicardipine 40 mg ordered “later today”; no administration charted yet
- Nurse note: pump programmed in mg/hour at 0.1 mg/mL; line labeled Cardene only
Answer key & rationale
Frequently asked questions
What should nurses check before starting nicardipine IV?
Confirm no advanced aortic stenosis, verify bag or vial concentration (0.1 or 0.2 mg/mL premixed, or 0.1 mg/mL after vial dilution), use a large peripheral or central vein, label a dedicated line, establish blood pressure goals, and plan oral transition before discontinuation.
When should the nicardipine infusion rate be decreased or stopped?
When unacceptable hypotension or tachycardia occurs, discontinue the infusion per the label. When blood pressure and heart rate stabilize, restart at low rates such as 3–5 mg/hour and reassess frequently.
How often should the IV site be changed?
Change the infusion site every 12 hours when nicardipine runs through a peripheral vein to reduce phlebitis and local irritation. Avoid small veins on the hand or wrist.
Can nicardipine share an IV line with other medications?
No. Cardene I.V. prescribing information states do not combine with any product in the same intravenous line or premixed container. Sodium bicarbonate and lactated Ringer’s are incompatible with vial formulations in the same tubing.
When should oral nicardipine start before stopping the IV drip?
When continuing the same drug orally, administer the first oral nicardipine dose 1 hour before discontinuing the IV infusion per labeling. When switching to a different oral antihypertensive, coordinate timing with the prescriber so IV is not stopped without coverage.
Is there a specific antidote for nicardipine overdose?
No specific reversal agent is listed. Expected effects are hypotension and reflex tachycardia; discontinue the infusion and provide supportive care including vasopressors for profound hypotension per protocol.
References
-
Baxter Healthcare Corporation. CARDENE IV (nicardipine hydrochloride) injection, solution. DailyMed (setid: a3e33add-0d09-423a-9109-42e5ba7148d5). Revised 03/2024.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3e33add-0d09-423a-9109-42e5ba7148d5
-
Baxter Healthcare Corporation. CARDENE IV (nicardipine hydrochloride) injection, solution — single-dose vial. DailyMed (setid: 5749599d-ff2a-42e4-aa72-cd25013feee8).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5749599d-ff2a-42e4-aa72-cd25013feee8
-
U.S. Food and Drug Administration. CARDENE IV premixed injection product labeling PDF.https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=a3e33add-0d09-423a-9109-42e5ba7148d5&type=pdf
-
NIH National Library of Medicine. LactMed: Nicardipine. Drugs and Lactation Database.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM408/
-
NICE British National Formulary. Nicardipine monograph.https://bnf.nice.org.uk/search?q=nicardipine
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.